Kuboki, Y., Pietrantonio, F., Salvatore, L., Meriggi, F. A., Modest, D. P., Yaeger, R., … Hong, D. S. (2025). 743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). In Annals of Oncology (Vol. 36, pp. S518–S519). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.1317

Kuboki, Y., F. Pietrantonio, L. Salvatore, F. A. Meriggi, D. P. Modest, R. Yaeger, E. Ruiz, et al. “743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).” In Annals of Oncology, 36:S518–19. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.1317.

Kuboki Y, Pietrantonio F, Salvatore L, Meriggi FA, Modest DP, Yaeger R, et al. 743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). In: Annals of Oncology. Elsevier BV; 2025. p. S518–9.

Kuboki, Y., et al. “743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S518–19. Crossref, doi:10.1016/j.annonc.2025.08.1317.

Kuboki Y, Pietrantonio F, Salvatore L, Meriggi FA, Modest DP, Yaeger R, Ruiz E, Taieb J, Karamouzis MV, Esaki T, Kim TW, Cremolini C, Strickler JH, Masuishi T, Paez D, Chan E, Chao J, Tran Q, Fakih M, Hong DS. 743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). Annals of Oncology. Elsevier BV; 2025. p. S518–S519.